Yahoo News
June 24, 2019
Pfizer Inc- PFE announced that the European Commission has approved its PARP inhibitor, Talzenna (talazoparib) for BRCA-mutated advanced breast cancer in previously-treated patients.
The drug is approved as monotherapy for treating locally advanced (“LA”) or metastatic breast cancer (“MBC”) patients with HER2 negative, germline breast cancer susceptibility gene (gBRCA)1/2-mutations. Patients must have received prior treatment with an anthracycline and/or a taxane in the (neo) adjuvant setting or they should be ineligible for treatment with anthracycline/ taxane.
The drug is also approved for use in patients with HR+ breast cancer who have received prior endocrine-based therapy or are unsuitable for endocrine-based therapy.
Talzenna is already approved in the United States for treating gBRCA mutated HER2-negative LA or MBC since October 2018.
Read the Full Article Here:
https://news.yahoo.com/pfizers-talzenna-gets-approval-europe-123312847.html